SCHEMBL2932908

SCHEMBL2932908

CC1(C)OB(c2ccc(O)c(C(=O)c3ccccc3)c2)OC1(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 1/20 0.50
LIPG Q9Y5X9 3/20 0.46
LPL P06858 2/20 0.46
LMNA P02545 4/20 0.43
MAPT P10636 3/20 0.43
HPGD P15428 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP3A4 P08684 1/20 0.43
RECQL P46063 1/20 0.43
HSD17B10 Q99714 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
GAA P10253 1/20 0.42
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
HIF1A Q16665 3/20 0.41
HTT P42858 2/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18241170 0.84 CSNK2A1 (0.47) P4HBLIPGLPLHPGDKDM4E
SCHEMBL30483000 0.83 HIF1A (0.40) P4HBHIF1AALDH1A1CA1CA2
SCHEMBL25981432 0.83 LIG1 (0.54) P4HBLIPGLPLCA1CA2
SCHEMBL1129340 0.82 P4HB (0.49) P4HBLIPGLPLLMNAMAPT
SCHEMBL1129235 0.82 ROCK1 (0.49) P4HBLIPGLPLLMNAMAPT
SCHEMBL14995786 0.81 HIF1A (0.45) P4HBLIPGLPLHIF1AROCK1
SCHEMBL5800648 0.81 P4HB (0.62) P4HBLIPGLPLHPGDALDH1A1
SCHEMBL1128778 0.80 MAPT (0.48) P4HBLIPGLPLLMNAMAPT
SCHEMBL30483081 0.80 HIF1A (0.46) P4HBLIPGLPLHIF1ACA1
SCHEMBL16828504 0.80 CA1 (0.48) P4HBLIPGLPLHIF1ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
EP-2044051-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (publ) (SE) 2009-04-08 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 P4HB 4808/4885LIPG 4062/4885LPL 3890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.